THOROFARE, N.J., June 16, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (Nasdaq: AKER ) (AIM:AKR.L), ("Akers Bio" or the "Company"), a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, is pleased to provide an update on the progress of the Company's Wellness division following the introduction in May of two new breath tests at the World Congress on Anti‐Aging Medicine (the "Congress").
"The response to the Akers Wellness products has been overwhelmingly positive," said Raymond F. Akers, Jr. PhD, Co‐founder and Executive Chairman. "Participation at the Congress was designed to raise awareness of these new tools to assist in weight loss and anti-aging programs, and to gather customer feedback, but in fact it resulted in several hundred reservations for products once commercial production begins in Q3," continued Dr. Akers.
The Wellness products, known as BreathScan OxiCheck™ ("OxiChek™") and BreathScan KetoChek™ ("KetoChek™"), together with the bluetooth-enabled reading device, BreathScan Lync™ - which synchs via an app on any mobile device - will enable consumers to monitor trends in critical metabolic processes. In addition, suppliers of nutritional supplements and diet plans, and health coaches in fitness centers, will be able to more effectively monitor and adjust the progress of their clients.
OxiChek™ is Akers' second generation disposable breath test to rapidly determine levels of oxidative stress (free radicals) in the body and, to the Company's knowledge, is the only device of its kind on the market. Frequent use of OxiChek™ may help consumers comply with and adhere to their regimen of nutritional supplementation for management of oxidative stress, which is implicated in many diseases, including cardiac, cancer and arthritic diseases.
KetoChek™ is the second generation of Akers Bio's disposable breath-based diagnostic device that rapidly determines if the subject is in the optimal fat-burning state for weight loss, known as ketosis. Achieving a state of ketosis is a goal of many individuals following low carbohydrate diets. KetoChek™ is a simple, non-invasive process to identify, track and monitor ketosis for individuals interested in maximizing weight loss, or fat-burning metabolism for endurance athletics. To the Company's knowledge, Akers Bio's rapid ketone tests are the only disposable, breath-based ketone detection devices on the market.
Since the Congress in May, Akers Bio has established several strategic partnerships intended to advance the commercialization of these products. This includes a partnership with SPRIM, an international marketing consulting firm, to develop marketing strategies and implement a targeted sales effort. With SPRIM, the Company has broadened its initial target market of multilevel marketing firms to now include fitness centers and diet plans, as well as the anti-aging, functional and integrative medicine sectors.
In addition, the Company has partnered with FirstApp, a software company which has developed mobile apps for leading international pharmaceutical firms. Akers Bio is working with FirstApp to develop iOS (Apple) and Android apps to work in tandem with the KetoChek™ and OxiChek™ breath test devices in a useful and consumer-friendly format. It is intended that the app will have the additional capability to gather data to link lifestyle changes with the use of Akers Bio's products.
"We believe that the response to the Akers Wellness product introduction sends a clear message that there is a strong demand for efficiently delivered personalized health information," added Dr. Akers. "KetoChek™ and OxiChek™ will address this growing demand in the considerable weight loss and anti-aging markets."
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be found at www.akersbiosciences.com . Follow us on Twitter @AkersBio .
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.
For more information: Akers Biosciences, Inc. Raymond F. Akers, Jr. PhD Executive Chairman of the Board Tel. +1 856 848 8698 finnCap (UK Nominated Adviser and Broker) Geoff Nash / Scott Mathieson (Corporate Finance) Steve Norcross (Broking) Tel. +44 (0)20 7220 0500 Taglich Brothers, Inc. (US Investor Relations) Chris Schreiber Tel. +1 917 445 6207 Email: Vigo Communications (UK Investor Relations) Ben Simons / Fiona Henson Tel. +44 (0)20 7016 9570 Email:
